Table 2.
Comparison of clinical variables between the overall series of patients and the series with liver biopsies pre- and post-90Y-RE
|
Baseline Characteristics | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Patients |
Age (years)* |
Time to RE** |
FU months*** |
Sex N° (%) |
PT site N° (%) |
Met N° (%) |
Liver involvement N° (%) |
PS N° (%) |
Pre BV N° (%) |
Pre CTX N° (%) |
|||||||
| M | F | Colon | Rectum | ≤ 4 | > 4 | <25% | > 25% | 0 | ≥ 1 | No | Yes | No | Yes | ||||
|
Overall Series (N = 50) |
64 |
19 |
14 |
37 |
13 |
41 |
9 |
21 |
29 |
20 |
7 |
35 |
15 |
39 |
11 |
45 |
5 |
| (34–38) |
(6–71) |
(2–49) |
(74) |
(26) |
(82) |
(18) |
(42) |
(58) |
(40) |
(54) |
(70) |
(30) |
(78) |
(22) |
(90) |
(10) |
|
|
Pre/Post RE series (N = 13) |
58 |
21 |
15 |
9 |
4 |
11 |
2 |
4 |
9 |
30 |
6 |
9 |
4 |
9 |
4 |
12 |
1 |
| (40–75) |
(9–53) |
(3–49) |
(69) |
(31) |
(85) |
(15) |
(31) |
(69) |
(60) |
(46) |
(69) |
(31) |
(69) |
(31) |
(92) |
(8) |
|
| P value | 0.11 | 0.50 | 0.99 | 0.49 | 0.99 | 0.54 | 0.54 | 0.99 | 0.49 | 0.99 | |||||||
* mean (range); ** Months from diagnosis to 90Y-RE; ***Follow up post-90Y-RE;
M, male; F, female; PT, Primary Tumor; Met, Metastases; PS, Performance Status; BV, bevacizumab; CTX, cetuximab.